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Introduction 1 
Permanent conductive hearing loss can result from otosclerosis, a disease in which abnormal 2 
bone growth may impede the movement of the stapes bone and impair cochlear function. 3 
Examinations of temporal bones suggest that the disease presents bilaterally in approximately 4 
70-80% of cases (Hueb et al., 1991; Menger & Tange, 2003). Temporal bone studies have 5 
estimated a prevalence for otosclerosis of between 2.5% (Declau et al, 2001) and 8.3% 6 
(Altman et al, 1967). These estimates represent the combined sum of both symptomatic 7 
(clinical otosclerosis) and asymptomatic (histologic otosclerosis) cases. The proportion of 8 
these cases that correspond to clinical otosclerosis, where the disease actually interferes with 9 
hearing function, has been estimated to be between 12% (Altman et al, 1967) and 15% 10 
(Guild, 1944). These data therefore suggest that the prevalence of clinical otosclerosis in the 11 
population lies between 0.3% and 1.2%. It is estimated that sensorineural hearing loss also 12 
arises in about 10% of clinical otosclerosis cases (Browning & Gatehouse, 1992; Ramsay & 13 
Linthicum, 1994) and accounts for approximately 5-6% of cases at large cochlear implant 14 
centres (Tange R., personal communication, 2016), which if accurate would correspond to a 15 
prevalence for mixed losses arising from otosclerosis of 0.1% or lower. 16 
 17 
Several treatment options are available for adults with a bilateral mixed hearing loss of a 18 
mild, moderate, or severe degree. If the hearing loss is mild, a conventional acoustic hearing 19 
aid can be sufficient to overcome the conductive and sensorineural components. A hearing 20 
aid may also be beneficial for a moderate-to-severe loss provided the aid can overcome the 21 
conductive component while still providing sufficient residual amplification to aid the 22 
sensorineural component. The conductive component of the loss may also be addressed by 23 
performing stapes surgery where a prosthesis is placed to restore the function of the fixed 24 
stapes bone. The sensorineural component may then be more readily aided using an acoustic 25 
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hearing aid. In cases where an acoustic hearing aid cannot provide sufficient amplification or 26 
is not tolerated (e.g. ear infections) or surgical correction is not appropriate, a bone-anchored 27 
hearing device (BAHD) may be used to deliver acoustical energy to the cochlea via bone 28 
conduction (Tjellström & Håkansson, 1995). In cases of moderate-to-severe loss where both 29 
acoustic and bone-anchored hearing aids are unsuccessful or contraindicated, a middle-ear 30 
implant may also be considered. 31 
 32 
In the United Kingdom (UK), the treatment options for individuals with a severe-to-profound 33 
mixed hearing loss are limited. The severity of the loss means that an acoustic hearing aid 34 
alone is unlikely to provide benefit without surgical intervention to address the conductive 35 
component. The rate of successful stapes surgery in this patient group has been estimated to 36 
be approximately 60% (defined as the closure of the air-bone gap to <10 dB) and lower than 37 
that observed in patients with mild or moderate losses (Kisilevsky et al, 2010). The capacity 38 
of a BAHD device to provide benefit in these patients is also limited by its ability to provide 39 
sufficient energy transfer to the cochlea to overcome the sensorineural component of the loss. 40 
The introduction of more powerful BAHDs has expanded the candidacy range but aiding 41 
those with more severe sensorineural losses is still restricted by feedback (Bosman et al, 42 
2006). Although individuals with bone-conduction thresholds between 60-90 dB HL are 43 
therefore unlikely to be aided satisfactorily by either acoustic or bone-anchored hearing aids, 44 
they also do not meet current UK candidacy criteria for cochlear implantation (NICE, 2009). 45 
 46 
The Direct Acoustic Cochlear Implant (DACI) was developed to address this gap in treatment 47 
options for individuals with a severe-to-profound mixed hearing loss (Häusler et al., 2008). 48 
The DACI is an active implantable device which is composed of two parts. The wholly-49 
implanted part comprises a receiver-stimulator and a fixation system that couples an artificial 50 
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incus to a conventional stapes prosthesis (Fig. 1). The external part comprises a speech 51 
processor that converts incoming sound into a digital signal that is transmitted to the 52 
implanted part via a radio-frequency coil. The receiver-stimulator decodes that digital signal 53 
and drives the actuator accordingly via a mechanical piston. By stimulating the intracochlear 54 
fluids directly, the DACI bypasses any existing conduction problems in the middle ear and 55 
can deliver acoustical energy directly to the cochlear perilymph of sufficient power to aid 56 
severe-to-profound sensorineural losses. 57 
 58 
Lenarz et al. (2013) conducted a case series study of the safety and efficacy of the DACI in 59 
15 patients with a severe-to-profound mixed hearing loss defined as bone-conduction 60 
thresholds poorer than 30 dB HL from 0.5 to 4 kHz and an air-bone gap of at least 30 dB at 3 61 
or more test frequencies. On average, implantation of the device did not impair air- or bone-62 
conduction thresholds, with bone-conduction thresholds improving at 0.75, 1, and 1.5 kHz 63 
post-operatively. The DACI also improved sound-field thresholds measured from 250 Hz to 8 64 
kHz. Among those patients who used a hearing aid pre-operatively, the DACI improved 65 
sound-field thresholds, sentence recognition, and word recognition in quiet. The results of 66 
this preliminary study suggest that the DACI may be efficacious in patients with a severe-to-67 
profound mixed hearing loss and with moderate bone-conduction thresholds (Busch et al., 68 
2013). 69 
 70 
Direct acoustic cochlear implantation is not currently provided in the UK. Evidence from a 71 
well-designed prospective evaluation of effectiveness that compared DACI to usual care 72 
would be required to support its provision. However, there is uncertainty over which 73 
comparator intervention(s) should be used to represent usual care. There is also uncertainty 74 
over the audiometric definition of the patient group whose needs are unmet by usual care and 75 
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who would therefore be included in the future trial. Finally, there is uncertainty over whether 76 
clinicians in the UK would support such a trial. A study was therefore conducted to address 77 
these areas of uncertainty and to inform the design of the future trial. 78 
 79 
Materials and Methods 80 
An online survey was constructed using the Survey MonkeyTM software. The patient group of 81 
interest was defined in accordance with the indications for the Codacs™ DACI manufactured 82 
by Cochlear Ltd., Sydney, Australia (Cochlear 2013) as follows: (a) Otosclerosis; (b) Bone 83 
conduction (BC) thresholds of 55 dB or worse; (c) Air conduction thresholds in the severe-to-84 
profound range; (d) Receive insufficient benefit from conventional hearing aids. It was also 85 
clarified that these patients should be assumed to be otherwise healthy and that they fall 86 
outside the candidacy guidelines for cochlear implantation in the UK following guidance 87 
from the National Institute for Health and Care Excellence (NICE 2009). 88 
 89 
An initial question asked about the professional group to which respondents belonged (ENT, 90 
Audiologist, Hearing therapist, Other) as this survey sought to explore the routine practice 91 
and views of the various professional groups responsible for the care of these patients. 92 
Respondents were then asked to consider a vignette that described the patient group of 93 
interest and indicate the preferred treatment option for these patients (Fig. 2). The treatment 94 
options were given as: ‘No intervention’, ‘Audiological / speech-language therapy’, 95 
‘Amplification with hearing aids’, ‘Combination of amplification and audiological / speech-96 
language therapy’, ‘Other (please specify)’, and ‘I don't know’. Respondents to the survey 97 
were also asked to indicate the important outcomes to assess when measuring clinical benefit 98 
in the patient group of interest. The available outcome domains were specified based on a 99 
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review of those assessed in previous clinical studies of DACI (Busch et al 2013; Lenarz et al 100 
2013) and are listed in Table 1. 101 
 102 
Finally, respondents were reminded of the characteristics of the patient group of interest 103 
before being asked three questions about the clinical appropriateness of the DACI device, 104 
whether respondents would be willing to refer these patients into a trial of the DACI device, 105 
and at what stage in their treatment would they be willing to refer. For the latter, the options 106 
given were: ‘Even before initial stapes surgery’, ‘Only after stapes surgery’, ‘Only after 107 
revision stapes surgery’, ‘Other (please specify)’, and ‘I don't know’. The DACI device was 108 
not described by name but rather as a device which: (a) Couples directly to the perilymph of 109 
the cochlea via a conventional stapes prosthesis; (b) Is capable of delivering sufficient gain to 110 
aid bone conduction thresholds of 55 dB or worse; (c) Involves the surgical placement of a 111 
receiver/stimulator similar to that of a cochlear implant; and (d) Involves the use of a behind-112 
the-ear sound processor similar to that used with a cochlear implant. 113 
 114 
A consensus process was conducted to identify inclusion criteria for a future trial of direct 115 
acoustic cochlear implantation. An initial face-to-face meeting of experts in otosclerosis was 116 
held at which attendees were presented with information on the surgical considerations and 117 
audiological management by clinical professionals who have experience with providing 118 
DACI. A facilitated discussion was then held around three topics: ‘Which patients do not 119 
benefit from current treatment options in the UK?’, ‘Who are potential candidates for 120 
DACI?’, and ‘What factors should guide the design of a future trial and would it be feasible?’ 121 
A transcript of the resulting discussions was analysed and used to generate statements around 122 
which a potential consensus could be reached. Two rounds of an online survey were 123 
conducted. In the first round, respondents were asked to state their level of agreement with 124 
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each of the resulting statements on a five-point Likert scale from ‘Strongly disagree’ to 125 
‘Strongly agree’. In the second round, respondents were shown the level of agreement that 126 
had been expressed in round 1 and asked to reconsider their response in light of that 127 
information. Consensus was considered to have been reached on a particular statement if at 128 
least 80% of respondents agreed with it. 129 
 130 
The survey and consensus exercise were advertised through national professional bodies: 131 
ENT UK for otolaryngologists, and both the British Academy of Audiology and British 132 
Society of Audiology for audiologists. Invitations to participate were also sent directly to 133 
clinicians working at major referral centres for otosclerosis in the UK. 134 
 135 
Results 136 
Thirty-two clinical professionals completed the online survey comprising nine ENT 137 
specialists, 22 audiologists, and one hearing therapist. All had experience of managing 138 
patients with advanced otosclerosis within the UK National Health Service (NHS). Of those, 139 
30 provided responses to the question about the preferred management options for patients 140 
with advanced otosclerosis (Fig. 2). All but two (93%; 95% CI 78.7 to 98.2) indicated that 141 
their preferred management would include amplification via conventional acoustic hearing 142 
aids with 11 (37%; 95% 21.9 to 54.5) also indicating that they would recommend hearing 143 
therapy in addition to amplification. Only two respondents suggested alternative treatment 144 
options, which were the provision of a bone anchored hearing device and cochlear 145 
implantation. 146 
 147 
Respondents’ choices for the most important outcome to assess when measuring treatment 148 
benefit are shown in Table 1. No outcome domain was chosen by a statistical majority of 149 
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respondents either as the most or second most important outcome. The most frequently 150 
chosen outcome across either response option was self-reported quality of life, with 55% of 151 
respondents (95% CI 37.5 to 71.6) selecting it as either the most or second most important 152 
outcome to assess treatment benefit. 153 
 154 
When asked about whether DACI would be an appropriate treatment option for the patient 155 
group of interest, 25 of the 29 respondents (86%; 95% 69.4 to 94.5) indicated that it was, 156 
with the remainder selecting ‘I do not know’. None indicated that it was inappropriate. All 157 
those who considered it appropriate also indicated a willingness to refer their patients into a 158 
future trial. However, there was variability in when respondents would be willing to refer 159 
patients with 9 (38%; 95% 21.2 to 57.3) willing to do so even before stapes surgery had been 160 
attempted and 8 (33%; 95% 18.0 to 53.3) willing only after stapes surgery had been carried 161 
out. One respondent indicated that they might be willing to refer before stapes surgery but 162 
only if further evidence for the effectiveness of the DACI was available. Three respondents 163 
listed other criteria for referral, which were: (1) only after revision stapes surgery; (2) only 164 
after discussion with the patient; and (3) only after full investigation of non-surgical aiding 165 
options. 166 
 167 
Nineteen clinical professionals participated in the consensus exercise. An analysis of the 168 
transcript of the face-to-face facilitated discussion identified sixteen statements around which 169 
consensus was considered possible. Table 2 lists these statements along with the levels of 170 
agreement after one and two rounds of voting. The consensus was that stapes surgery, either 171 
with or without a hearing aid, is the best available treatment for advanced otosclerosis and a 172 
hearing aid trial is recommended prior to surgery, if that patient is willing. Bone-anchored 173 
hearing devices are an option for some patients and a headband trial would always 174 
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recommended, but the limit of candidacy for these devices is considered to be BC thresholds 175 
at 50 dB HL. Bone-anchored hearing devices are considered to be not powerful enough for 176 
patients whose BC thresholds are greater than 55 dB HL. 177 
 178 
The consensus was that there is a lack of clear alternative treatment options for those who 179 
have already received the best available treatment, who are outside criteria for both bone 180 
conduction hearing devices and cochlear implantation, and who still receive insufficient 181 
benefit from their hearing aids. These patients would therefore be referred for an implantable 182 
intervention such as a DACI as long as the odds of the patient receiving additional benefit 183 
over their hearing aids were favourable and similar to those expected for benefit from a 184 
cochlear implant. The consensus was also that further trials are needed and that would be 185 
supported by clinical professionals involved in the management of these patients. 186 
 187 
Discussion 188 
It is perhaps as informative to examine the statements that did not reach the required level of 189 
agreement as it is to identify where consensus was reached. The survey responses suggest 190 
that stapes surgery would still be offered to some patients with an air-bone gap as small as 20 191 
dB. The willingness of respondents to carry out stapes surgery even when benefit could be 192 
limited due to poor cochlear function could reflect the fact that pre-operative bone conduction 193 
levels may under-estimate the actual benefit achievable from stapes surgery (Shea et al., 194 
1999). However, the observed consensus on the need for favourable odds of improvement to 195 
warrant referral for a DACI suggests that there will be a lower limit of cochlear function 196 
beyond which clinicians will not be willing to refer patients. It is therefore important for 197 
future studies to characterise the relationship between pre-operative speech perception and 198 
the odds of a favourable outcome following the provision of a DACI device. Such an 199 
  9 
approach can be used to define candidacy criteria based on the likelihood that the patient will 200 
improve following the intervention (UKCISG, 2004). However, studies should also consider 201 
the size of change that would be considered meaningful from clinical and patient 202 
perspectives. 203 
 204 
It would also seem logical to assume that there will be an upper limit for the speech 205 
perception abilities of these patients beyond which DACI would either been seen as 206 
unnecessary or inappropriate. However, consensus was not reached on a statement that 207 
restricted referral to those with speech discrimination up to 50% correct, a threshold that has 208 
previously been used to define insufficient benefit from acoustic hearing aids in patients with 209 
more profound losses (NICE 2009). The failure to reach consensus on this point could reflect 210 
a belief that the threshold for referral should be more or less restrictive, but it could also be 211 
that respondents believed ‘insufficient benefit from hearing aids’ cannot be defined 212 
adequately or reliably in terms of a fixed threshold on a test of speech perception conducted 213 
in the artificial environment of an audiology testing booth. In the absence of an agreed 214 
threshold, such a judgement could be based on patient self-report of benefit in real life 215 
situations following the confirmed completion of a hearing aid trial. 216 
 217 
The failure to reach a consensus on whether clinicians were willing to refer for a DACI where 218 
a conductive component remained suggests that referral would be conditional on the outcome 219 
of stapes surgery in those patients where surgery would be recommended. However, the 220 
group failed to reach consensus on a general statement indicating that stapes surgery would 221 
be required before referral for a DACI could be recommended. This result is compatible with 222 
the fact that the needs of patients for whom stapes surgery is not recommended were 223 
considered to be unmet by the available treatment options. Their apparent willingness to refer 224 
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some patients for a DACI even without having conducted stapes surgery could also have 225 
reflected their views on the needs of patients with losses that are predominantly sensorineural 226 
in origin. The current study did not ask about such patients as it fell outside the current 227 
labelling of the device at the time the study was conducted (Cochlear, 2013). 228 
 229 
The current study aimed to inform the design of a future trial of DACI in the UK, including 230 
identifying the target patient population for whom the intervention is appropriate and needed. 231 
Table 3 lists proposed inclusion and exclusion criteria for a trial based on an analysis of the 232 
statements upon which the respondents reached consensus. The results of the current practice 233 
survey and the consensus exercise both suggest that the trial design needs to account for two 234 
groups: (1) those for whom stapes surgery is recommended where referral for a DACI would 235 
only be supported after that surgery has been conducted; (2) those for whom stapes surgery 236 
would not be clinically appropriate and for whom referral would be supported without prior 237 
surgical intervention. In both cases, the comparator to the DACI should be a trial of an 238 
acoustic hearing aid in combination with hearing therapy. Respondents’ views on important 239 
outcome domains suggest that the primary end-point for the trial should be an assessment of 240 
quality of life. Previous early-phase evaluations of the DACI have used a well-established 241 
measure of the impact of listening difficulties on everyday life (the Abbreviated Profile of 242 
Hearing Aid Benefit (APHAB); Cox & Alexander, 1995) and have suggest that outcomes 243 
could be assessed as early as three months after the intervention is provided (Lenarz et al., 244 
2013). The resulting trial design is shown in Figure 3. 245 
 246 
Prior to conducting such a trial, a feasibility study would be required to assess such practical 247 
issues as the learning curves of surgeons, the structure of the clinical pathway following 248 
provision of a DACI, and the nature and content of post-operative rehabilitation that would 249 
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be required. The willingness of patients to accept both randomization and the intervention 250 
itself would also need to be confirmed. Should a randomized controlled trial be unacceptable 251 
to patients or not be feasible to conduct, alternative approaches such as the creation of a 252 
matched control group from existing patients populations using propensity score matching 253 
could be considered (McCulloch et al., 2009). In that approach, patients are drawn from a 254 
control group based on their similarity to a smaller group of patients who receive the 255 
treatment on factors that could influence outcome. 256 
 257 
The current study identified quality of life as the outcome domain most frequently chosen by 258 
respondents. This result is one of two key pieces of information that are necessary to 259 
determine the required sample size for the future trial (Williamson et al 2012). The other is 260 
the smallest difference on that outcome that could be considered to be clinically important 261 
and is referred to as the minimal clinically-important difference (MCID) (Gatchel et al 2010). 262 
While the most important outcome domain can be identified through the use of surveys and 263 
consensus techniques (Sinha et al 2011), as demonstrated in the current study, the MCID is 264 
determined by relating the change in outcome to whether the patient perceived a change or 265 
not. The size of the change in outcome among those reporting no change in their hearing 266 
provides an estimate of the minimally-important difference (Jaeschke et al 1989). Further 267 
work would be required to identify an instrument that measures those aspects of quality of 268 
life that are relevant to the specific patients of interest (Buchbinder et al., 2011). Early-phase 269 
studies have already suggested that the APHAB is sensitive to the reductions in everyday 270 
listening difficulty that occur following the provision of a DACI (Lenarz et al., 2013). 271 
 272 
The current study suggests that there is a patient population for whom there is a lack of 273 
treatment options and for whom direct stimulation of the cochlea via the implantation of an 274 
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auditory prosthesis is considered an appropriate intervention. There appears to be strong 275 
support amongst the clinical professionals who manage the care of these patients to conduct a 276 
clinical trial to evaluate the effectiveness of this novel intervention. A feasibility study is now 277 
necessary to determine how many patients would be required for that future trial, whether 278 
those patients could be recruited within a reasonable timeframe, and whether the proposed 279 
trial design would be acceptable to patients. 280 
 281 
  282 
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Figure captions 345 
Figure 1: A photograph of the implanted component of a direct acoustic cochlear 346 
implant system (left) and a computer rendering of the fixation system (right) used to 347 
attach the mechanical actuator (5) to a conventional stapes prosthesis. 1: Removable 348 
magnet; 2: Receiver coil; 3: implant electronics; 4: lead assembly; 5: actuator; 6: rod; 7: 349 
artificial incus. Reproduced from the surgical instructions for use (Cochlear, 2013).  350 
Figure 2: The clinical vignette used to assess the preferred management option for the 351 
target patient group with advanced otosclerosis. 352 
 353 
Figure 1 Click here to download Figure (TIFF, PDF, Word Doc, PPT, or EPS files are
acceptable) Figure 1.tiff
An otherwise healthy patient 
with otosclerosis currently 
wears two hearing aids. They 
have had stapes surgery 
which closed the air-bone 
gap to less than 10 dB. Their 
post-operative audiogram is
shown on the right. However, 
they still report receiving 




Bilateral otosclerosis with severe-profound mixed 
loss reporting insufficient benefit from hearing aids
Usual care
Hearing aid fitting and trial 
with hearing therapy
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Not recommended or performed previously
3-month follow-up
Assessment of outcomes 
including quality of life
3-month follow-up
Assessment of outcomes 
including quality of life
Figure 3
 Table 1: Respondents choices for the most important outcome to assess when measuring treatment benefit in adults with advanced 
otosclerosis. The outcome domains have been sorted based on the proportion of respondents who identified them as the ‘most 
important’ outcome to measure to assess treatment effect. The values in parentheses represent the number of respondents. 
Outcome domain Most important 2nd most important Total 
Quality of life reported by the patient 38% (11) 17% (5) 55% (16) 
Ability to understand speech in quiet listening conditions 17% (5) 21% (6) 38% (11) 
Ability to understand speech in noisy listening conditions 17% (5) 14% (4) 31% (9) 
Level of listening difficulty reported by the patient 14% (4) 17% (5) 31% (9) 
I don't know 7% (2) 0% (0) 7% (2) 
Ability to localise sounds (tell where they are coming from) 3% (1) 0% (0) 3% (1) 
Level of effort required to listen reported by the patient 3% (1) 10% (3) 14% (4) 
Sensitivity to sound (e.g. pure-tone/soundfield audiometry) 0% (0) 7% (2) 7% (2) 
Other 0% (0) 0% (0) 0% (0) 
 
Table 1
 Table 2: Level of agreement across 19 participants in the consensus process with 16 statements generated from the initial open round. 
Statement Round 1 
Round 
2 
I would always recommend a hearing aid trial to patients with advanced otosclerosis before stapes surgery, as long as the patient is willing. 93% 95% 
For otosclerosis patients with BC thresholds worse than 55 dB but who are also outside of CI criteria, either a hearing aid alone or in combination 
with stapes surgery is the best treatment that is currently available. 
93% 95% 
I would not recommend stapes surgery for cases of advanced otosclerosis with sloping high-frequency loss because the risks would outweigh the 
potential benefits to speech perception. 
36% 16% 
I would not recommend stapes surgery to patients with advanced otosclerosis if their speech discrimination is worse than 30% correct. 57% 37% 
There is currently a lack of treatment options for otosclerosis patients with BC thresholds worse than 55 dB, who are outside of CI criteria, and 
who still struggle with HAs after receiving stapes surgery or if surgery is not recommended. 
79% 89% 
For patients whose BC thresholds are worse than 55 dB and who are not close to CI criteria, I would not recommend stapes surgery if their air-
bone gap is less than 20 dB. 
64% 63% 
I would consider a bone-anchored hearing device for a patient with otosclerosis if their BC thresholds are better than 55 dB. 71% 74% 
Patients with otosclerosis whose BC thresholds are 50 dB are approaching the limits of what a bone-anchored hearing device can aid. 86% 89% 
I would always recommend a headband trial before surgery to provide a bone-anchored hearing device. 93% 89% 
The acoustic gain of a bone-anchored hearing device is insufficient for otosclerosis patients with BC thresholds worse than 55 dB. 86% 89% 
I would always recommend stapes surgery to patients with advanced otosclerosis before referring them for a new implantable intervention. 64% 68% 
I would not refer otosclerosis patients whose needs are currently unmet by currently-available treatments for a new implantable intervention if 
their speech discrimination is better than 50% correct. 
57% 26% 
I would refer otosclerosis patients whose needs are currently unmet by currently-available treatments for a new implantable intervention, as long 
as there is at least an 80% chance of the patient receiving additional benefit. 
71% 89% 
I would refer otosclerosis patients whose needs are currently unmet by currently-available treatments for a new implantable intervention even if a 
conductive component remained, as long as I am sure that their previous stapes surgery was done competently. 
64% 68% 
Clinical trials are needed to evaluate new treatments for otosclerosis patients whose needs are currently unmet by currently-available treatments. 100% 100% 
I would support clinical trials to evaluate treatments for otosclerosis patients whose needs are currently unmet by currently-available treatments. 100% 100% 
 
Table 2
 Table 3: Suggested inclusion and exclusion criteria for a trial of DACI in the United Kingdom. 
Inclusion criteria 
Bilateral severe-to-profound hearing loss defined as average AC thresholds > 70 dB HL1 
Bilateral otosclerosis 
BC thresholds worse than 55 dB HL 
Where recommended, has undergone stapes surgery that closed the air-bone gap to within 10 dB2 
Completed a hearing aid trial 
Exclusion criteria 
Reports receiving sufficient benefit from acoustic hearing aids 
Simultaneously satisfies both of the following criteria:3 
1. A score of less than 50% on Bamford–Kowal–Bench (BKB) sentence testing at a sound intensity of 70 dB SPL 
2. AC thresholds >90 dB HL at 2 and 4 kHz 
1 Following definition of categories of hearing loss from British Society of Audiology (2011) 
2 Following definition of a resolved conductive component from Kisilevsky et al (2010) 
3 Following guidance on the candidacy criteria for cochlear implantation from NICE (2009) 
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